20091841

Source:http://linkedlifedata.com/resource/pubmed/id/20091841

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0008838, umls-concept:C0010583, umls-concept:C0087111, umls-concept:C0144576, umls-concept:C0205265, umls-concept:C0282460, umls-concept:C0677886, umls-concept:C1522577, umls-concept:C1555582
pubmed:issue	6
pubmed:dateCreated	2010-3-10
pubmed:abstractText	The objective of this study was to assess activity and toxicity in patients with newly diagnosed, advanced-stage epithelial ovarian cancer (EOC) who were receiving dose-intense paclitaxel, cyclophosphamide, cisplatin, and filgrastim delivered with a flexible dosing schedule.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/ZIA SC009375-17
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-10623700, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-12529997, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-1376773, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-14656276, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-16343237, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-16343238, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-16460787, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-16716797, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-16716800, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-17393164, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-17499348, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-17512352, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-18287387, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-18420499, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-19224846, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-7494563, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-7541159, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-7602348, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-7695986, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-7865431, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-7912534, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-8751547, http://linkedlifedata.com/resource/pubmed/commentcorrection/20091841-9888470
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide, http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel
pubmed:status	MEDLINE
pubmed:month	Mar
pubmed:issn	0008-543X
pubmed:author	pubmed-author:FullerArlan FAF, pubmed-author:GoodmanAnnekathrynA, pubmed-author:HussainMahrukh MMM, pubmed-author:KohnElise CEC, pubmed-author:MinasianLoriL, pubmed-author:NikruiNajmosamaN, pubmed-author:ReedEddieE, pubmed-author:SarosyGisele AGA, pubmed-author:SeidenMichael VMV, pubmed-author:SteinbergSeth MSM
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	116
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1476-84
pubmed:dateRevised	2011-7-26
pubmed:meshHeading	pubmed-meshheading:20091841-Adenocarcinoma, pubmed-meshheading:20091841-Adult, pubmed-meshheading:20091841-Aged, pubmed-meshheading:20091841-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:20091841-Cisplatin, pubmed-meshheading:20091841-Cyclophosphamide, pubmed-meshheading:20091841-Drug Administration Schedule, pubmed-meshheading:20091841-Female, pubmed-meshheading:20091841-Humans, pubmed-meshheading:20091841-Middle Aged, pubmed-meshheading:20091841-Ovarian Neoplasms, pubmed-meshheading:20091841-Paclitaxel, pubmed-meshheading:20091841-Prognosis, pubmed-meshheading:20091841-Treatment Outcome
pubmed:year	2010
pubmed:articleTitle	Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.
pubmed:affiliation	Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, MSC 1906, Bethesda, MD 20892-1906, USA.
pubmed:publicationType	Journal Article, Clinical Trial, Phase II, Research Support, N.I.H., Intramural